Wednesday, July 8, 2026

Patent intelligence · US

US 10800734

Memantine compounds and their preparation and uses thereof

granted A61KA61K31/225A61K31/235A61K31/27
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 121
Patent details — US 10800734
Jurisdiction
US
Status
granted
Grant date
Oct 13, 2020
Expiration
Oct 8, 2040
Claims
15
CPC classes
A61K, A61K31/225, A61K31/235, A61K31/27
View on Google Patents ↗

Quick answer

US 10800734 (Memantine compounds and their preparation and uses thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Oct 13, 2020. Expires Oct 8, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K31/225, A61K31/235, A61K31/27, A61K31/445, A61K31/473

More from SUNSHINE LAKE PHARMA CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 10800734?

US 10800734 (Memantine compounds and their preparation and uses thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Oct 13, 2020. Expires Oct 8, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10800734?

SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 10800734 expire?

Our index shows an expiration date of Oct 8, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.